



PSUBRAMONY@FULBRIGHT.COM
DIRECT DIAL: (512) 536-3067


FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

TELEPHONE: (512) 474-5981
FACSIMILE: (512) 536-4598

RECEIVED
MAY 30 2002
TECH CENTER 16001290
#3

May 23, 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
May 23, 2002	
Date	Priya D. Subramony

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 09/998,009 entitled "CDDO-COMPOUNDS AND COMBINATION THERAPIES THEREOF" by Marina Konopleva et al.*
Client Reference: MDA00-010
Our Reference: UTSC:652US


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C27).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10109288/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Priya D. Subramony
Patent Agent
Reg. No. 50,939

PDS/cmb
Encl.: as noted

25166776.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Marina Konopleva *et al.*

Serial No.: 09/998,009

Filed: November 28, 2001


For: CDDO-COMPOUNDS AND
COMBINATION THERAPIES THEREOF



Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: UTSC:652US




CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

May 23, 2002

Date


Priya D. Subramony

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10109288/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Priya D. Subramony
Reg. No. 50,939
Agent for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: May 23, 2002

Form PTO-1449 (modified)

Atty. Docket No.
UTSC:652USSerial No.
09/998,009

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
November 28, 2001Group:
1614U.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Agarwal and Mehta, "Possible involvement of Bcl-2 pathway in resinoid X receptor alpha-induced apoptosis of HL-60 cells," <i>Biochem Biophys Res Commun</i> , 230(2):251-253, 1997.
	C2	Andreeff <i>et al.</i> , "Expression of bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and cationic acid," <i>Leukemia</i> , 13:1881-1892, 1999.
	C3	Andreeff, "Acute myeloid leukemia," <i>In: Cancer Treatment</i> , Haskell (Ed.), W. B. Saunders, 911-922, 1995.
	C4	Beran <i>et al.</i> , "Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia," <i>J. Clinical Oncology</i> , 17(9):2819-2830, 1999.
	C5	Carter <i>et al.</i> , "Expression of survivin, a member of the inhibitor of apoptosis (IAP) family of caspase inhibitors is expressed in AML and regulated by cytokines and ATRA," <i>Blood</i> , 94(Suppl 1):479a, Abstract # 2142, 1999.
	C6	Castaigne <i>et al.</i> , "All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia," <i>Blood</i> , 76(9):1704-1709, 1990.
	C7	Drach <i>et al.</i> , "Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid," <i>Cancer Research</i> , 53:2100-2104, 1993.

25117808.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:652US

09/998,009

List of Patents and Publications for Applicant's

Applicant

Marina Konopleva *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

November 28, 2001

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Engel <i>et al.</i> , "Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells," <i>Leukemia</i> , 13:568-577, 1999.
	C9	Estey <i>et al.</i> , "Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia," <i>Blood</i> , 94:2230-2235, 1999.
	C10	Estey <i>et al.</i> , "Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin + all-trans retinoic acid + granulocyte-colony stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrom," <i>Blood</i> , 93(8):2478-2484, 1998.
	C11	Kim <i>et al.</i> , "Capasase-3 activation is involved in apoptosis induced by a synthetic triterpenoid in Non-small cell lung cancer (NSCLC) cells," <i>Proc. Amer. Assoc. Cancer Res.</i> , 41:770, Abstract #4894, 2000.
	C12	Konopleva and Andreeff, "Regulatory pathways in programmed cell death," <i>Cancer Mol Biol.</i> , 6:1229-1260, 1999.
	C13	Konopleva <i>et al.</i> , "Apoptosis: molecules and mechanisms," <i>Adv Exp Med Biol</i> , 457:217-236, 1998.
	C14	Konopleva <i>et al.</i> , "Engraftment potential of AML progenitors into NOD/scid mice is dependent on baseline CXCR4 expression," <i>Blood</i> , 94(Suppl 1):166b, Abstract #3916, 1999.
	C15	Konopleva <i>et al.</i> , "Novel synthetic triterpenoid, CDDO, and its methyl ester: Potent antiproliferative, proapoptotic and differentiating agents in AML," <i>Blood</i> , 94(Suppl 1):479a, Abstract #2140, 1999.
	C16	Konopleva <i>et al.</i> , "Novel triterpenoid CDD0-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia," <i>Blood</i> , 99(1):326-335, 2002.
	C17	Konopleva <i>et al.</i> , "PPAR γ nuclear receptor as a novel therapeutic target in AML," <i>Blood</i> , 96(11):460a, Abstract #1982, 2000.
	C18	Kornblau <i>et al.</i> , "Apoptosis regulating proteins as targets of therapy for hematological malignancies," <i>Exp. Opin. Inv. Drugs</i> , 8:2027-2057, 1999.
	C19	Kornblau <i>et al.</i> , "Phase I study of mitoxantrone plus etoposide with multidrug blockage by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia," <i>J. Clin. Oncol.</i> , 15(5):1796-1802, 1997.

25117808.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



RECEIVED
MAY 30 2002
TECH CENTER 1600/2900

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:652US

09/998,009

List of Patents and Publications for Applicant's

Applicant

Marina Konopleva *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

November 28, 2001

Group:

1614

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C20	Mehta <i>et al.</i> , "Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells," <i>Cell, Growth Differ</i> , 7(2): 179-186, 1996.
	C21	Sporn <i>et al.</i> , "Prospects for prevention and treatment of cancer with selective PPAR γ modulators (SPARMs)," <i>Trends in Molecular Medicine</i> , 7(9):395-400, 2001.
	C22	Suh <i>et al.</i> , "A novel synthetic oleanane triterpenoid, 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity," <i>Cancer Res.</i> , 59(2):336-341, 1999.
	C23	Tamm <i>et al.</i> , "Expression and prognostic significance of IAP-family genes in human cancers and leukemias," <i>Blood</i> , 94(Suppl. 1):69a, Abstract # 298, 1999.
	C24	Walczak <i>et al.</i> , "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand <i>in vivo</i> ," <i>Nature Medicine</i> , 5(2):157-163, 1999.
	C25	Wang <i>et al.</i> , "A synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma," <i>Mol.Endocrinol.</i> , 14(10): 1550-1556, 2000.
	C26	Warrell <i>et al.</i> , "Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)," <i>N. Engl. J. Med.</i> , 324(20):1385-1393, 1991.
	C27	Xie <i>et al.</i> , "Differential expression patterns in human myeloblastic leukemia HL-60 and multidrug resistant HL-60/Dox cells analyzed by human cDNA expression array," <i>Blood</i> , 92 (Suppl 1):387a, Abstract #1600. 1998.

25117808.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)